Retatrutid 20mg we yu de yuz

▎ Ritatrutid Strukchɔ

Sos: PubChem

Sikεns: YA⊃1;QGTFTSDYSI-L⊃2;LDKK4AQA⊃1;AFIEYLLEGGPSSGAPPPS⊃3; Mɔlikul Fɔmula: C 221H 342N 46O68 Molikul Weyt: 4731 g/mol CAS Nɔmba: 2381089-83-2 PubChem CID: 171390338, ɛn di ɔda wan dɛn Sinonim dɛn:LY3437943

▎ Risach we dɛn kɔl Retatrutid

Wetin na di risach bakgrɔn fɔ Retatrutid?

Di risach bakgrɔn fɔ Retatrutid gɛt fɔ du wit di bad bad tin dɛn we de apin na di wɔl we gɛt fɔ du wit fat ɛn dayabitis, ɛn bak di limiteshɔn dɛn we di tritmɛnt drɔgs dɛn we de naw gɛt: fat ɛn dayabitis de mek pipul dɛn gɛt siriɔs trɛt fɔ pɔblik wɛlbɔdi, wit di pipul dɛn we fat na di wɔl we dɛn dɔn prɔjɛkt fɔ rich 4.005 bilyan bay 2035 ɛn di nɔmba fɔ di wan dɛn we gɛt dayabitis go go ɔp to 592 milyɔn, we kin mek dɛn spɛn bɔku mɔni pan wɛlbɔdi biznɛs na di wɔl bikɔs ɔf dayabitis. di mכlti-target rεsεptכr agonist pεpti dεm dכn kכmכt as sכlushכn, we ebul fכ mek i nכ fat, trit dayabεtis, εn fכ avכyd di tכxik sayd ifekt dεm we di drog dεm we de naw de gi, we de mek dεn bi wan tεnd fכ divεlכp fכ fat εn dayabitis tritmεnt.

Wetin na di mɛkanism fɔ akshɔn fɔ Retatrutid?

rεgulεt εnεji mεtabolism tru mכlti-rεsεptor aktibכshכn

rεtatrutid na tripl rεsεpכta agonist we de tכk to di glukכs-dipεndεnt insulinotropik pכlipεptida rεsεptכr (GIPR), glukכgכn lεk pεptida-1 rεsεpכta (GLP-1R), εn glukagכn rεsεpכta (GCGR). i de aktibכt dεn tri rεsεpכta dεm ya wan tεm, we de rεgεl di εnεji mεtabolism tru mכltipכl path dεm.

GIPR agonist akshɔn: . 

GIP na כmon we de kכmכt na di intestinal insulin we di intestinal K sεl dεm de kכmכt εn we de kכmכt afta it. Retatrutid de mek di GIPR wok, i de mek insulin sekreshכn, i de mek di insulin sεnsitiviti bכku, εn dat de εp di bכdi fכ abzכp εn yuz glukכs mכr ifektiv wan, we de mek di blכd glukכs lεvεl dכn. apat frכm dat, GIP kin infכlכw di fεt mεtabolism bay we i de rεgεl di adiposyt fכnshכn εn rεdכks fεt akyumyuleshכn ^[1]..

GLP-1R agonist aktiviti: 

GLP-1 na pεptida כmon we di intestinal L sεl dεm de kכl. afta we i aktibכt GLP-1R, Retatrutid de prodyuz difrεn bεnεfit ifekt dεm. i kin mek insulin sekreshכn insay wan we we dipεnd pan glukכs kכnsantreshכn, we de mek di bכdi shuga lεvεl dכn. I kin mek di bɛlɛ nɔ ɛmti, i kin mek pɔsin satis, ɛn i kin mek i nɔ it bɛtɛ. GLP-1R agonism kin akt bak pan di sεntri nεv sεstem, we de rεgεl di apεtit εn εnεji bεlε, we de εp fכ lכs di wet ^[2]..

GCGR agonist ifekt dɛn: 

glukagon tipikli de inkrεs di blכd glukכs lεvεl, bכt כnda di inflכεns fכ Retatrutid, GCGR agonism de prodyuz difrεn ifekt dεm. i de protεkt glycogenolysis εn gluconeogenesis insay di liva. כnda di kכmbayn ifekt dεm we Retatrutid de gi, di bכdi nכ de εkspiriεns simpul inkrεs pan di blכd glukכs lεvεl bכt insted i de rεgεl εnεji mεtabolism fכ inkrεs fεt brεk dכwn, we de achy fכ lכs weit εn impruv mεtabolism. GCGR agonism kin infכlכp di hεpatik lipid mεtabolism bak, we de ridyus di hεpatik fεt akyumyuleshכn ^{[3] .}.

Efεkt dεm pan Mεtabolism-Rεlatεd Fysiolojikal Prכsεs dεm

bay we i de akt wan tεm pan di tri rεsεpכta dεm we wi bin dכn tכk bכt, Retatrutid de infכlכp mכltipכl mεtabolism-rεlatεd fysiolojikal prכsεs dεm.

Di we aw dɛn de rigul di glukɔs na di blɔd: 

bay we dεn aktibכt GIPR εn GLP-1R fכ protεkt insulin sekreshכn, εn we dεn rεgεl GCGR fayn fayn wan, Retatrutid kin lכs di blכd glukכs lεvεl. di haypoglycemic ifekt we i de gi de sho we di glukose na di blɔd go ɔp, pan ɔl we i nɔ go izi fɔ mek i mek di glucose na di blɔd nɔmal, we go bɛnifit fɔ kɔntrol di glucose na di blɔd pan di wan dɛn we gɛt dayabitis ^[4]..

We yu de kɔntrol yu wet: 

Retatrutid de sho se i gɛt impɔtant ɛfifikɛshɔn pan wet mɛnejɛmɛnt. bay we i de aktibכt GLP-1R, i de slo di gastric εmpti, i de mek di satiety bכku, εn i de ridyus di it we yu de it; bay we i de rεgεl di fεt mεtabolism, i de mek di fεt brok dכn εn di εnεji we i de spεnd, we de mek i lכs di wet. Klinik trial dɔn sho se di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we dɛn trit wit Retatrutid kin gɛt bɔku bɔku wet fɔ lɔng tɛm ^[5,6]..

Lipid rεgulεshכn: . 

Retatrutid tritmɛnt de mek di sik pipul dɛn lipid profayl bɛtɛ. i de ridyus di triglisεrayd (TG), lכw dεnsiti lipoprotein kכlestכl (LDL-C), εn vεri lכw dεnsiti lipoprotein kכlestכl (VLDL-C) lεvεl dεm, we i de rεgεl di apolipoprotein dεm bak, lεk fכ lכs di apolipoprotein B (apoB) εn apolipoprotein C -III (apoC-III) lεvεl, we de ridyus di nכmba fכ di lipoprotein patikyula dεm we de asosiet wit atεrosklεrosis εn fכ mek di kכdivaskyul hεlth ^{[7] .}.

Impruv di hεpatik lipid mεtabolism: 

Fɔ di pasɛnt dɛn we gɛt nɔ-alkohol fat liva sik (NAFLD) we gɛt fɔ du wit mɛtabolik disfɔkshɔn, Retatrutid de ridyus di epatik fat kɔntinyu bad bad wan. Insay rilevɛns klinik trayal, di pasɛnt dɛn we dɛn trit wit difrɛn doz dɛn fɔ Retatrutid sho se dɛn gɛt signifyant rilitiv ridyushɔn pan di liva fat kɔntinyu we dɛn kɔmpia am wit di beslayn, we sho se Retatrutid gɛt pɔsitiv rɛgyulatɔri ifɛkt pan di liva fat mɛtabolism, we fayn fɔ mek di liva wok fayn ^[3]..

Figure 1 di mεkanism dεm we Retatrutid de du ^[8]..

Wetin na di aplikeshɔn dɛn fɔ Retatrutid?

Di tritmɛnt fɔ di wan dɛn we fat: 

Fat pasmak dɔn bi wan big big pɔblik wɛlbɔdi biznɛs na di wɔl, we gɛt fɔ du wit di biginin ɛn di prɔgrɛs fɔ difrɛn sik dɛn we nɔ de mɛn. Retatrutid dɔn sho se i gɛt bɔku pawa fɔ trit pipul dɛn we fat pasmak. Di wan dɛn we fat we dɛn trit wit Retatrutid bin gɛt wan notis ridɔkshɔn pan dɛn bɔdi wet. Insay wan 48 wik Faz 2 ɔbisiti stɔdi, di pasɛnt dɛn we dɛn trit wit 8mg ɛn 12mg Retatrutid bin gɛt weit ridɔkshɔn pan 22.8% ɛn 24.2%, rispɛktvɔli. Insay wan ɔda Faz 2 dɛbul-blaynd, randomized, plasɛbo-kɔntrol trial, pasɛnt dɛn we de na difrɛn doz grup dɛn bin gɛt difrɛn digri dɛn fɔ lɔs dɛn wet na 24 wik ɛn 48 wik. Di 12mg grup bin ajɔst wan wet lɔs fɔ 24.2% na 48 wik, we di plasɛbo grup bin jɔs si ridyushɔn fɔ -2.1%. Retatrutid de ridyus bɔdi wet fayn fayn wan pan pipul dɛn we fat, we de gi nyu ɛn pawaful tin fɔ trit pipul dɛn we fat. Retatrutid tritmɛnt fɔ fat nɔr jɔs de ridyus bɔdi wet bɔt i kin ɛp ɔda wɛlbɔdi prɔblɛm dɛn we gɛt fɔ du wit fat, lɛk fɔ stɔp di strɛs we pɔsin kin gɛt we i de bia wit di jɔyn dɛn ɛn fɔ mek i nɔ gɛt di sik dɛn we pɔsin kin gɛt we i fat pasmak tru di wet we i de lɔs; fכ ridyus di wet kin εp bak fכ impruv di kכmplikεshכn dεm we de kכmכt frכm fכ fat lεk slip apnea ^[3,6]..

Tayp 2 dayabitis tritmɛnt: 

Tayp 2 dayabitis na wan kכmכn krεse mεtabolik dizכrd wae de kכl insulin rεsistεns εn nכ insulin sekreshכn. Retatrutid gɛt pɔtɛnɛshɛl aplikeshɔn valyu fɔ trit tayp 2 dayabitis. i de mek insulin sekreshכn bay we i de aktibכt di GLP-1 rεsεpכta, i de mek insulin rεsistεns bεtε, εn i de mek di blכd glukכs lεvεl dכn. Di tin dɛn we i kin du fɔ ridyus di wet kin ɛp bak fɔ mek di wan dɛn we gɛt tayp 2 dayabitis gɛt bɛtɛ wɛlbɔdi, bikɔs fɔ fat na impɔtant tin we kin mek pɔsin gɛt tayp 2 dayabitis, ɛn we pɔsin lɔs in wet kin mek pɔsin gɛt mɔ insulin, ɛn dis kin ɛp mɔ fɔ kɔntrol di glukɔs na di blɔd. Insay stεdi dεm we involv pasεn dεm wit tayp 2 dayabεtis, Retatrutid bin lid to signifyant weit lכs εn wan notabl rεdukshכn pan hεmoglobin A1c (HbA1c) lεvεl, wit HbA1c dεkrεshכn bay 1.64% kכmpεr to plasεbo. Dis sho se Retatrutid nɔ jɔs de kɔntrol di blɔd glukɔs lɛvɛl fayn fayn wan bɔt i de ɛp fɔ mek di ɔl kɔndishɔn fɔ di wan dɛn we gɛt tayp 2 dayabitis bɛtɛ tru bɔku we dɛn, we inklud fɔ lɔs dɛn wet, ɛn dis de mek dɛn kwaliti layf bɛtɛ ^[6]..

Nɔn-alkohol fat liva sik (NAFLD) tritmɛnt: 

NAFLD na mεtabolik strεs-indyuz liva injuri we kכlכsכl wit insulin rεsistεns εn jεnεtik susεptibiliti, we inkכmpas wan spεktrum כf kכndishכn dεm we inklud nכn-alkohol simpul fεt liva, nכn-alkohol stεatohepatitis, εn rilatεd sirosis. Retatrutid sho prɔmis pɔtnɛshɛl na NAFLD tritmɛnt. In wan randomized, double-blind, placebo-controlled trial we involv patisipan dεm wit mεtabolik dysfunction-associated fεt liva sik εn liva fεt kכntεnt ≥10%, na 24 wik, di min rilitiv chenj in liva fεt kכntεnt frכm beslayn bin sכmtεm difrεnt across Retatrutid doz grup dεm: -81.4% in di 8mg grup, -82.4% in di 12 mg grup, ɛn +0.3% na di plesibo grup. Dis sho se Retatrutid kin ridyus di liva fat we de insay di liva fayn fayn wan, we rili impɔtant fɔ mek di liva patɔlɔji fɔ di wan dɛn we gɛt NAFLD bɛtɛ. I gɛt prɔmis as nyu tritmɛnt opshɔn fɔ NAFLD, we kin mek di sik slo ɛn ridyus di risk fɔ gɛt siriɔs kɔmplikeshɔn lɛk sirosis ^[3]..

Dɔn

Retatrutid sho prכmis pכtεnshal fכ impruv di hεpatik patכlayz stetכs fכ NAFLD pasεnshכn dεm, we de akt tru mכltipכl mεkanism dεm we inklud fכ rεgεl εnεji mεtabolism, impruv insulin rεsistεns, anti-inflammatory ifekt dεm, εn mכdulet lipid mεtabolism.

Bɔt di pɔsin we rayt di buk

Di tin dɛm we wi dɔn tɔk bɔt ɔp na ɔl di risach, ɛdit ɛn kɔmpilayt na Cocer Peptides.

Sayɛns Jɔnal Author

Rosenstock, J na wan ɔda masta sabi bukman we in wok gɛt fɔ du wit sɔm big big institiushɔn dɛn, lɛk di Yunivasiti ɔf Tɛksas Sawt Wɛstɛn Mɛdikal Sɛnta, di Yunivasiti ɔf Tɛksas Dalas, ɛn di Kanada VIGOR Senta. In risach span bɔku fild dɛm lɛk Ɛndokrinɔlɔji & Mɛtabolism, Jɛnɛral & Intanɛt Mɛdisin, Kadiɔvaskyuɛl Sistɛm & Kadiɔlɔji, Famakɔlɔji & Famasi, ɛn Risach & Ɛkspirimɛnt Mɛdisin. In wɔndaful kɔntribyushɔn to di akademik kɔmyuniti dɔn mek bɔku pipul dɛn no am, as dɛn pruv am bay we dɛn pik am bɔku tɛm as 'Highly Cited Researcher in the field of Clinical Medicine' frɔm 2017 to 2024, we sho in impɔtant pozishɔn ɛn dip inflɔɛns we i gɛt pan klinik mɛdikal risach. Rosenstock J de list in di rεfrεns fכ saytεshכn [4].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Brzozowska P, Frańczuk A, Nowinska B, ɛn ɔda pipul dɛn. Retatrutid - rivכlyushכn rεsεntli divεlכp GLP agonist - litεrachכ rivyu[J]. Kwaliti in Spɔt, 2024.DOI: 10.12775/qs.2024.15.52125.

[2] Doggrell S A. Retatrutid we de sho prɔmis pan fat (ɛn tayp 2 dayabitis)[J]. Ekspɛkt Opinion Pan Investigeshɔn Drug, 2023,32(11):997-1001.DOI:10.1080/13543784.2023.2283020.

[3] Sanyal A. J., Kaplan L. M., Frias J. P., ɛn ɔda pipul dɛn. Tripul hכmon rεsεptכr agonist Retatrutid fכ mεtabolik disfכnkshכn-asכsiet stεatotik liva sik: wan randomizεd fεz 2a trayal[J]. Nature Mεdisin, 2024, 30: 2037-2048.DOI: 10.1038/s41591-024-03018-2.

[4] Rosenstɔk J, Frias J, Jastrebɔf A. M., ɛn ɔda pipul dɛn. Retatrutid, na GIP, GLP-1 ɛn glukagon rεsεptכr agonist, fכ pipul dεm we gεt tayp 2 dayabεtis: wan randomizεd, dכbl-blaynd, plasεbo εn aktv-kכntrol, paralel-grup, fεz 2 trayal we dεn kכnεkt na di USA[J]. Lancet, 2023,402(10401):529-544.DOI:10.1016/S0140-6736(23)01053-X.

[5] Jastreboff A. M., Kaplan L. M., Frías J. P., ɛn ɔda pipul dɛn. Tripl-Hכmon-Rεsεptor Agonist Rεtatrutid fכ Obesiti - Wan Faz 2 Trayal[J]. Nyu Ingland Jɔnal fɔ Mɛdisin, 2023,389(6):514-526.DOI:10.1056/NEJMoa2301972.

[6] Lopez D. C., Pajimna J. T., Milan M. D., ɛn ɔda pipul dɛn. 7792 Efficacy of Retatrutid fכ Weight Ridukshכn εn In Cardiometabolic Efεkt dεm bitwin Adult dεm: A Sistεmatik Rivyu εn Mεta-Analysis[J]. J ɔ rnal ov di Ɛndokrin Sɔsayti, 2024,8(1):163-749.DOI:10.1210/jendso/bvae163.749.

[7] Nicholls S, Pirro V, Lin Y, ɛn ɔda pipul dɛn. tripl-hכmon rεsεptכr agonist Retatrutid de impruv lipoprotein εn apolipoprotein profayl dεm bכku bכku wan pan patisipan dεm we fat כ ova wet[J]. Yuropian At Jɔnal, 2024,45(1):666-1501.DOI:10.1093/eurheartj/ehae666.1501.

[8] Katsi V, Koutsopoulos G, Fragoulis C, ɛn ɔda pipul dɛn. Retatrutid—A Game Changer in Obisiti Famakotɛrapi: Bayomɔlikul dɛn[Z]. 2025: 15.DOI: 10.3390/bayɔm15060796.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL DI INFƆMƐSHƆN DISƐMƐNƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.